Refine Your Search

At the completion of this activity, the participant will be able to: State the major advances in clinical cardiology in the past decade; Summarize the changing concomitant disorders affecting cardiovascular treatment; Identify new pharmacotherapy impacting the treatment of cardiovascular disease; and Recognize new treatment targets in cardiology over the next 10 years.

The Cardiovascular Symposium is an annual live educational series created by the Divisions of Cardiology and Cardiothoracic Surgery at The University of Toledo. The symposium is designed to bring cardiologists, internists, cardiac surgeons, family physicians, nurses, pharmacists, and other health care professionals up-to-date with new concepts in the diagnosis, treatment and management of patients with heart disease. Additionally, healthy living habits are promoted.

Statins have had a significant effect on coronary heart disease risk since their introduction. However, a residual risk for cardiovascular events persists. In addition to lowering LDL levels, clinicians must be aware of how to manage patients with low HDL levels and high triglycerides. Statins may have an affect on these lipids as well. This monograph will review the impact of statins on lipid profiles, as well as potential adverse events and drug interactions. Strategies to improve statin saf...

Meets ACR CME Requirements for Accreditation in BOTH CT and MR! A globally renowned society for almost 40 years, NASCI encourages the development and dissemination of knowledge regarding Cardiovascular Imaging through its highly acclaimed annual meetings. The 2010 Annual Meeting is available here, containing nearly thirty hours of presentations and cases in Cardiac CT, Cardiac MR, Pediatric Imaging, Heart Disease and much more! Learn from the finest minds in this emerging specialty! 28 ...

he purpose of this meeting is to provide the needed information distilled in a manner that can be applied to clinical practice. The scope of the program is broad and will cover a wide spectrum of topics in CHF/heart transplant, coronary artery diseases, cardiac arrhythmias, adult congenital heart diseases among others. Participants will learn about the new anticoagulants available to use in patients with atrial fibrillation techniques, percutaneous aortic and pulmonic valve replacement and new...

It is impossible to separate cardiovascular from metabolic disease when it comes to risk assessment, prevention, and clinical intervention. The biggest health problem facing the world today is from the combined impact of obesity, diabetes, and cardiovascular disease. No other conference address the breadth and depth of this new paradigm like the Cardiometabolic Health Congress (CMHC) – imparting the scientific basis and clinical tools essential to combat cardiometabolic risk. It is cri...

Cardiology continues to advance in the development of new diagnostic and therapeutic treatments. The intent of the program is to provide the most current evidence based treatment strategies for your patients. The program will include topics such as: pulmonary hypertension, new lipid guidelines, heart disease in women, CHF, hypertension, device and medical therapy for heart failure, treatment of atrial fibrillation, management of peripheral vascular disease, congenital heart disease in adults, ...

After completing this activity, the participant should be able to: - Review the different cardiovascular conditions commonly encountered in patients with diabetes. - Discuss the metabolic syndrome and its importance in controlling diabetes. - Discuss different methods for controlling diabetes and related heart disease complications. - Describe the available medications dealing with cardiovascular complications in individuals with diabetes.

Description: The Lipids Unresolved webcast reviews the latest research, knowledge, and skills needed to identify patients who remain at risk for cardiovascular (CV) events, and evaluate emerging strategies that decrease residual CV risk. Expert faculty presenters include their perspectives and interpretations of current clinical trial data regarding the future management of patients with cardiovascular disease. Learning Objectives: -Discuss the effect of HDL-C level on risk for CHD. ...

Statins have significantly reduced the risk of cardiovascular events for most patients. For some patients, there are obstacles to statin therapy that although rare, must be addressed, including rhabdomyolysis and myopathy. Strategies including switching agents, reducing dosages, adjusting dosing schedules and adding non-statin agents in order to improve tolerability while still providing cardiovascular benefit. Special attention must be paid to the use of statins in the elderly, and in patient...

•List two situations where pharmacologic stress is preferred over exercise stress for myocardial perfusion imaging. •Recite evidence from myocardial perfusion imaging for increased ischemic burden. •Discuss the conditions associated with nonperfusion indices of ischemia

Cardiovascular disease is a disease process that affects the heart and/or vasculature. This course, intended for intermediate learners, provides a review of cardiovascular disease, including structures and organs affected, the signs and symptoms associated with disease processes, and how these symptoms may affect mobility, quality of life and participation in therapy. It includes a review of medications used for treatment, associated side effects and precautions that may impact therapy, and st...

Purpose Statement A 10-year follow up of the original Lipid Treatment Assessment Project (L-TAP) survey was recently published. Overall, 73% of patients reached their LDL-C goal; in high-risk patients, the rate was 67%. Despite this improvement, in high-risk patients (i.e., CHD plus ≥2 major risk factors such as diabetes, hypertension, and smoking), the results are less impressive as one third of these patients remain inadequately treated. Using the more recently recommended optional LDL-C ...

EDUCATIONAL OBJECTIVES At the end of the program, participants should be able to: Cardiovascular Symposium, June 4-5 • Recognize the differences in CV risk for type I and II diabetics • Interpret and utilize the 2011 Guidelines for heart disease prevention in women • State which vascular diagnostic imaging tests that should be used in women • Diagnose cognitive function and dementia in aging women • Apply strategies to implement lifestyle behavior change for weight management,...

* Compare second-line lipid lowering agents for special patient populations * Assess carotid artery media thickness as a clinical endpoint * Evaluate the primary literature of ezetimibe versus niacin as a guide for therapy management of cardiovascular risk reduction

Program Overview Cardiovascular disease (CVD) is the leading cause of morbidity and mortality among people with chronic kidney disease (CKD). While the link between CVD and CKD is apparent, primary care providers are not effectively screening and treating patients with renal disease who are at enhanced risk for cardiovascular disease and events. Physicians should institute appropriate screening techniques into practice to be better able to identify patients with CKD, since they are at incr...

International thought leaders will discuss the safety data and clinical implications of dal-PLAQUE and dal-VESSEL and the future implications for strategies that modulate HDL with the intent of reducing cardiovascular risk.

The program focuses on the education needs of cardiologists, surgeons, and radiologists who treat peripheral vascular diseases. The program is also intended for other health-care providers, including nurses and advanced practice nurses, podiatrists, endocrinologists, primary care providers, wound care specialists, as well as radiology, cardiovascular and vascular laboratory technologists. As in prior years, Vascular Care 2013 also has a special session on the emerging specialty of vascular n...

Management of cardiovascular disease is a rapidly changing area of clinical practice, with emerging research and practice altering widely accepted tenets. While the importance of treating dyslipidemias based on cardiovascular risk factors is highlighted by the NCEP ATP III clinical practice guidelines, recent clinical trials reveal the focus on dyslipidemia treatment cannot solely rely on aggressive LDL-C targets. The study shows that subjects who received treatment and achieved significant ...

The purpose of the Introduction to Cardiovascular Pharmacology Self-Learning Packet is to present an overview of some of the more commonly used cardiovascular drugs, broken down by classification, and to provide basic guidelines for safe administration by licensed healthcare providers.

This packet was designed for licensed healthcare professionals who care for patients with heart failure. While comprehensive this packet is intended to be an overview. Prerequisites for this package include a working knowledge of basic cardiovascular anatomy and physiology, hemodynamics and cardiovascular pharmacology.

This packet was designed for nursing personnel who care for patients with pulmonary artery catheters in the critical care units. Prerequisites for this packet are a working knowledge of basic cardiovascular anatomy and physiology, cardiovascular pharmacology, and basic ECG interpretation skills.

Cardiovascular diseases are the most common cause of mortality and morbidity accounting for more than 40% of total mortality in Western countries. Most of this is due to acute coronary syndrome (ACS), including ST and non-ST elevation myocardial infarction. An optimal pharmacologic approach in these patients is of major importance with a particular emphasis on the antiplatelet regimen, which remains the cornerstone of the initial ACS treatment at hospital admission and during percutaneous coro...

Diabetes significantly increases a patient’s risk of atherosclerotic events. Leading clinicians will evaluate and explain how the implementation of therapeutic lifestyle changes, diet and exercise along with appropriate medication can improve HDL levels and attenuate cardiovascular risk in the patient with type 2 diabetes. The safety and efficacy of treatment strategies for diabetic dyslipidemia will be addressed, including CETP inhibition, an emerging approach that increases HDL concentrati...

Session 1 – Monday, November 12, 2012 - Focus on Cardiovascular Disease Session 2 – Thursday, November 15, 2012 - Focus on Endocrine Disease Session 3 – Friday, November 16, 2012 - Focus on Aging and Mental Illness

Internal Medicine Update 2012 offers practical and timely clinical recommendations and guidelines for general internists and subspecialists, family practice physicians, physician assistants, nurse practitioners and allied healthcare professionals. Several interactive, collaborative Breakout sessions of your choice, on topics relevant to your clinical practice, are available. Courses required for Florida medical license renewals (Medical Errors and Domestic Violence) are included. Sessions a...

Fulfill your Vascular Lab CME Requirements with this globally revered course! For over twenty years, this annual symposium has provided a comprehensive update on vascular imaging and diagnosis. The newest edition is available here on DVD-ROM, focusing on real time B-mode imaging, color and spectral Doppler and other non-invasive techniques. The course will also address important issues in the area of Vascular Laboratory management, vascular ultrasound education, reimbursement and laboratory...

NEEDS ASSESSMENT As a result of participants’ evaluations and community physician annual needs assessment surveys, the requirements for contemporary evaluation and management of heart and vascular disease by the primary care practitioner have been identified. This evidence-based learning activity has been designed to alter physician performance in areas indicated in the needs assessments, including selection of management for cardiac risk factors, including lipid disorders, hypertension, an...

Cardiovascular disease is the leading cause of death among patients with type 2 diabetes, and patients with diabetes are three times more likely to experience coronary heart disease than healthy patients. In this program leading clinicians will identify the pathophysiologic connections between type 2 diabetes and cardiovascular risk and describe management strategies to minimize this risk for patients.

Limitations of clopidogrel therapy for acute coronary syndromes (ACS) have led to the conduct and completion of clinical outcome trials investigating different approaches to reduce ischemic risk. These different approaches include alternative dosing strategies with clopidogrel, as well as more potent oral antiplatelet agents. Clinical trials of these more potent agents versus clopidogrel are resulting in significant changes to the landscape of oral antiplatelet therapy. With the completion of ...